MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- International - mnc pharma
- GSK PHARMA - ACTAVIS (US)
GSK PHARMA vs ACTAVIS (US) - Comparison Results
GSK PHARMA Change
GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More
ACTAVIS (US)
Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More
Financials
 GSK PHARMA  ACTAVIS |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| GSK PHARMA Mar-19 |
ACTAVIS Dec-18 |
GSK PHARMA/ ACTAVIS |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 3,595 | 14,487 | - | |
| Low | Rs | 1,253 | 9,718 | - | |
| Sales per share (Unadj.) | Rs | 184.7 | 3,553.7 | - | |
| Earnings per share (Unadj.) | Rs | 26.3 | -1,144.7 | - | |
| Cash flow per share (Unadj.) | Rs | 29.2 | 374.5 | - | |
| Dividends per share (Unadj.) | Rs | 20.00 | 0 | - | |
| Dividend yield (eoy) | % | 0.8 | 0 | - | |
| Book value per share (Unadj.) | Rs | 126.3 | 14,657.5 | - | |
| Shares outstanding (eoy) | m | 169.40 | 332.60 | - | |
| Bonus/Rights/Conversions | - | - | - | ||
| Price / Sales ratio | x | 13.1 | 3.4 | 385.4% | |
| Avg P/E ratio | x | 92.2 | -10.6 | -871.9% | |
| P/CF ratio (eoy) | x | 83.1 | 32.3 | 257.2% | |
| Price / Book Value ratio | x | 19.2 | 0.8 | 2,324.0% | |
| Dividend payout | % | 76.1 | 0 | - | |
| Avg Mkt Cap | Rs m | 410,626 | 4,025,370 | 10.2% | |
| No. of employees | `000 | 5.0 | 16.9 | 29.3% | |
| Total wages/salary | Rs m | 5,372 | 0 | - | |
| Avg. sales/employee | Rs Th | 6,306.7 | 69,939.2 | 9.0% | |
| Avg. wages/employee | Rs Th | 1,083.1 | 0 | - | |
| Avg. net profit/employee | Rs Th | 898.0 | -22,527.5 | -4.0% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 31,281 | 1,181,973 | 2.6% | |
| Other income | Rs m | 1,023 | 22,603 | 4.5% | |
| Total revenues | Rs m | 32,304 | 1,204,576 | 2.7% | |
| Gross profit | Rs m | 6,009 | 30,974 | 19.4% | |
| Depreciation | Rs m | 486 | 505,268 | 0.1% | |
| Interest | Rs m | 6 | 68,207 | 0.0% | |
| Profit before tax | Rs m | 6,540 | -519,897 | -1.3% | |
| Minority Interest | Rs m | 0 | 0 | - | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 287 | 132,595 | 0.2% | |
| Tax | Rs m | 2,373 | -6,589 | -36.0% | |
| Profit after tax | Rs m | 4,454 | -380,714 | -1.2% | |
| Gross profit margin | % | 19.2 | 2.6 | 733.0% | |
| Effective tax rate | % | 36.3 | 1.3 | 2,863.2% | |
| Net profit margin | % | 14.2 | -32.2 | -44.2% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 20,061 | 484,783 | 4.1% | |
| Current liabilities | Rs m | 14,543 | 428,855 | 3.4% | |
| Net working cap to sales | % | 17.6 | 4.7 | 372.8% | |
| Current ratio | x | 1.4 | 1.1 | 122.0% | |
| Inventory Days | Days | 57 | 20 | 289.9% | |
| Debtors Days | Days | 14 | 66 | 21.2% | |
| Net fixed assets | Rs m | 14,343 | 133,793 | 10.7% | |
| Share capital | Rs m | 1,694 | 0 | - | |
| Net worth | Rs m | 21,398 | 4,875,085 | 0.4% | |
| Long term debt | Rs m | 2 | 1,716,694 | 0.0% | |
| Total assets | Rs m | 39,113 | 7,620,868 | 0.5% | |
| Interest coverage | x | 1,091.0 | -6.6 | -16,474.4% | |
| Debt to equity ratio | x | 0 | 0.4 | 0.0% | |
| Sales to assets ratio | x | 0.8 | 0.2 | 515.7% | |
| Return on assets | % | 11.4 | -4.1 | -278.1% | |
| Return on equity | % | 20.8 | -7.8 | -266.5% | |
| Return on capital | % | 31.9 | -4.8 | -659.6% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 3,994 | 422,274 | 0.9% | |
| From Investments | Rs m | -1,433 | 231,985 | -0.6% | |
| From Financial Activity | Rs m | -3,584 | -724,749 | 0.5% | |
| Net Cashflow | Rs m | -1,023 | -70,138 | 1.5% | |
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 74.87 Rs / USD
Compare GSK PHARMA With: ADCOCK INGRAM (S. Africa) MYLAN (US) TEVA PHARMA (Israel)
Compare GSK PHARMA With: GLENMARK PHARMA CIPLA AJANTA PHARMA PROCTER & GAMBLE HEALTH LUPIN
Today's Market
Sensex Ends 244 Points Lower, Nifty Ends Below 14,300; UltraTech Cement & HCL Tech Top Losers(Closing)
Indian share markets witnessed volatile trading activity throughout the day today and ended lower.
Related Views On News
GSK PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 124.4% (Quarterly Result Update)
Feb 10, 2021 | Updated on Feb 10, 2021For the quarter ended December 2020, GSK PHARMA has posted a net profit of Rs 2 bn (up 124.4% YoY). Sales on the other hand came in at Rs 9 bn (up 10.2% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.
GSK PHARMA Announces Quarterly Results (2QFY21); Net Profit Down 84.8% (Quarterly Result Update)
Oct 30, 2020 | Updated on Oct 30, 2020For the quarter ended September 2020, GSK PHARMA has posted a net profit of Rs 765 m (down 84.8% YoY). Sales on the other hand came in at Rs 9 bn (down 0.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.
GSK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)
Jun 24, 2019 | Updated on Jun 24, 2019Here's an analysis of the annual report of GSK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GSK PHARMA. Also includes updates on the valuation of GSK PHARMA.
More Views on NewsMost Popular
India: Recovery Stalled by Vaccine Games? (The Honest Truth)
Apr 13, 2021Ajit Dayal on how India's vaccine strategy will impact the markets.
A Stock with 700% Return Potential Comes with Additional Payoffs (Profit Hunter)
Apr 15, 2021Narayana Murthy was one of the first unicorn founders to get the backing of this entity...
11x Bankruptcy to Bluechip Stock: A Rare India Revival Story (Profit Hunter)
Apr 16, 2021There is no stopping this 11-bagger stock from significant upside.
Top 3 Nifty ETFs to Buy Now (Fast Profits Daily)
Apr 20, 2021In this video I tell you the three Nifty ETFs I think are the best.
Why Did the Market Crash on Monday? (Fast Profits Daily)
Apr 13, 2021In this video, I'll you what I think is the real reason behind yesterday's market crash.
More
